Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
Nov. 22, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, a groundbreaking biopharmaceutical company focused on advancing immune system-stimulating therapeutics for cancer treatment, has announced its participation in a fireside chat at the upcoming Evercore ISI HealthCONx Conference. The discussion, featuring Werewolf Therapeutics’ President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will take place on November 29 at 8:20 AM ET in Miami, Florida.
During the chat, Werewolf Therapeutics will present their pioneering approach to developing conditionally activated therapeutics that engage the body’s immune system to combat cancer. With their proprietary PREDATORâ„¢ platform, the company is able to design molecules that activate both adaptive and innate immunity, aiming to overcome the limitations of traditional proinflammatory immune therapies. The company’s lead candidates, WTX-124 and WTX-330, are systemically delivered Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, intended for the treatment of solid tumors.
WTX-124 is currently being developed as a monotherapy, as well as in combination with KEYTRUDA® (pembrolizumab), for multiple solid tumor types. On the other hand, WTX-330 is in development as a single agent for advanced or metastatic solid tumors and non-Hodgkin lymphoma that have shown refractory or unresponsive behavior to immunotherapy. The unique attribute of these molecules is their ability to remain inactive in peripheral tissue while selectively activating within the tumor microenvironment.
The Evercore ISI HealthCONx Conference will provide a platform for Werewolf Therapeutics to showcase their groundbreaking work and engage in meaningful discussions with industry leaders and investors. Audience members can access the live webcast of the conference presentation at https://investors.werewolftx.com/news-and-events/events. A recorded replay of the presentation will also be available on the website for approximately 90 days following the event.
These advancements in immuno-oncology hold immense promise for cancer patients worldwide, as Werewolf Therapeutics continues to push the boundaries of therapeutic innovation. As they present their progress at the prestigious Evercore ISI HealthCONx Conference, the company remains committed to its mission of revolutionizing cancer treatment through groundbreaking immune system activation.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc. is a leading clinical-stage biopharmaceutical company dedicated to developing cancer therapeutics that stimulate the body’s immune system. Leveraging their proprietary PREDATORâ„¢ platform, the company designs conditionally activated molecules that activate both adaptive and innate immunity, addressing the limitations of conventional immune therapies. Their lead molecules, WTX-124 and WTX-330, are designed for the treatment of solid tumors, offering new hope to patients facing limited treatment options.
For more information, please visit the Werewolf Therapeutics website at https://www.werewolftx.com/.
Disclaimer: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause the company’s actual results to differ materially from those projected. Such forward-looking statements include statements regarding the company’s ability to revolutionize cancer treatment and advance the development of conditionally activated therapeutics. Any forward-looking statements made in this communication are based on assumptions as of the date of this press release. The company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or otherwise.
